nach oben

Erschienen in:

12.05.2020 | Original Article

Disease course of lung oligometastatic colorectal cancer treated with stereotactic body radiotherapy

verfasst von: Luca Nicosia, Francesco Cuccia, Rosario Mazzola, Francesco Ricchetti, Vanessa Figlia, Niccolò Giaj-Levra, Michele Rigo, Davide Tomasini, Nadia Pasinetti, Stefanie Corradini, Ruggero Ruggieri, Filippo Alongi

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 9/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Stereotactic body radiotherapy (SBRT) or stereotactic ablative radiotherapy (SABR) has been shown to increase survival rates in oligometastatic disease (OMD), but local control of colorectal metastases remains poor. We aimed to explore the natural course of oligometastatic colorectal cancer and to investigate how SBRT of lung metastases can delay the progression to polymetastatic disease (PMD).

Methods

107 lung oligometastases in 38 patients were treated with SBRT at a single institution. The median number of treated lesions was 2 (range 1–5). Time to PMD (ttPMD) was defined as the time from SBRT to the occurrence of >5 new metastases. Genetic biomarkers such as EGFR, KRAS, NRAS, BRAF, and microsatellite instability were investigated as predictive factors for response rates.

Results

Median follow-up was 28 months. At median follow-up, 7 patients were free from disease and 31 had progression: 18 patients had sequential oligometastatic disease (SOMD) and 13 polymetastatic progression. All SOMD cases received a second SBRT course. Median progression-free survival (PFS) was 7 months (range 4–9 months); median ttPMD was 25.8 months (range 12–39 months) with 1‑ and 2‑year PFS rates of 62.5% and 53.4%, respectively. 1‑ and 2‑year local PFS (LPFS) rates were 91.5% and 80%, respectively. At univariate analysis, BRAF wildtype correlated with better LPFS (p = 0.003), SOMD after primary SBRT was associated with longer cancer-specific survival (p = 0.031). Median overall survival (OS) was 39.5 months (range 26–64 months) and 2‑year OS was 71.1%.

Conclusion

The present results support local ablative treatment of lung metastases using SBRT in oligometastatic colorectal cancer patients, as it can delay the transition to PMD. Patients who progressed as SOMD maintained a survival advantage compared to those who developed PMD.

Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64(1):9–29CrossRefPubMed

Elias D, Liberale G, Vernerey D et al (2005) Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol 12:900–909CrossRefPubMed

Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, Mulroy L, Lock M, Rodrigues GB, Yaremko BP, Schellenberg D, Ahmad B, Griffioen G, Senthi S, Swaminath A, Kopek N, Liu M, Moore K, Currie S, Bauman GS, Warner A, Senan S (2019) Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet 393(10185):2051–2058. https://doi.org/10.1016/S0140-6736(18)32487-5CrossRefPubMed

Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, Dingemans AC, Fournier B, Hurkmans C, Lecouvet FE, Meattini I, Méndez Romero A, Ricardi U, Russell NS, Schanne DH, Scorsetti M, Tombal B, Verellen D, Verfaillie C, Ost P (2020) Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol 21(1):e18–e28. https://doi.org/10.1016/S1470-2045(19)30718-1CrossRefPubMed

Alongi F, Arcangeli S, Filippi AR, Ricardi U, Scorsetti M (2012) Review and uses of stereotactic body radiation therapy for oligometastases. Oncologist 17(8):1100–1107. https://doi.org/10.1634/theoncologist.2012-0092CrossRefPubMedPubMedCentral

Petrelli F, Comito T, Barni S, Pancera G, Scorsetti M, Ghidini A, SBRT for CRC liver metastases (2018) Stereotactic body radiotherapy for colorectal cancer liver metastases: a systematic review. Radiother Oncol 129(3):427–434. https://doi.org/10.1016/j.radonc.2018.06.035CrossRefPubMed

Osti MF, Agolli L, Valeriani M, Reverberi C, Bracci S, Marinelli L, De Sanctis V, Cortesi E, Martelli M, De Dominicis C, Minniti G, Nicosia L (2018) 30 Gy single dose stereotactic body radiation therapy (SBRT): report on outcome in a large series of patients with lung oligometastatic disease. Lung Cancer 122:165–170. https://doi.org/10.1016/j.lungcan.2018.06.018CrossRefPubMed

Agolli L, Bracci S, Nicosia L, Valeriani M, De Sanctis V, Osti MF (2017) Lung metastases treated with Stereotactic ablative radiation therapy in Oligometastatic colorectal cancer patients: outcomes and prognostic factors after long-term follow-up. Clin Colorectal Cancer 16(1):58–64. https://doi.org/10.1016/j.clcc.2016.07.004CrossRefPubMed

Klement RJ, Abbasi-Senger N, Adebahr S, Alheid H, Allgaeuer M, Becker G, Blanck O, Boda-Heggemann J, Brunner T, Duma M, Eble MJ, Ernst I, Gerum S, Habermehl D, Hass P, Henkenberens C, Hildebrandt G, Imhoff D, Kahl H, Klass ND, Krempien R, Lewitzki V, Lohaus F, Ostheimer C, Papachristofilou A, Petersen C, Rieber J, Schneider T, Schrade E, Semrau R, Wachter S, Wittig A, Guckenberger M, Andratschke N (2019) The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases. BMC Cancer 19(1):173. https://doi.org/10.1186/s12885-019-5362-5CrossRefPubMedPubMedCentral

10.

Qiu H, Katz AW, Chowdhry AK, Usuki KY, Singh DP, Metcalfe S, Cheruvu P, Chen Y, Okunieff P, Milano MT (2018) Stereotactic body radiotherapy for lung metastases from colorectal cancer: prognostic factors for disease control and survival. Am J Clin Oncol 41(1):53–58. https://doi.org/10.1097/COC.0000000000000220CrossRefPubMed

11.

Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, Karasawa K, Hayakawa K, Niibe Y, Takai Y, Kimura T, Takeda A, Ouchi A, Hareyama M, Kokubo M, Kozuka T, Arimoto T, Hara R, Itami J, Araki T (2011) Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys 81(5):1352–1358. https://doi.org/10.1016/j.ijrobp.2009.07.1751CrossRefPubMed

12.

Li S, Dong D, Geng J, Zhu X, Shi C, Zhang Y, Wang H, Zhou S, Wu H, Cai Y, Li Y, Wang W (2019) Prognostic factors and optimal response interval for stereotactic body radiotherapy in patients with lung oligometastases or oligoprogression from colorectal cancer. Front Oncol. https://doi.org/10.3389/fonc.2019.01080CrossRefPubMedPubMedCentral

13.

Miller JA, Kotecha R, Ahluwalia MS, Mohammadi AM, Chao ST, Barnett GH, Murphy ES, Vogelbaum MA, Angelov L, Peereboom DM, Suh JH (2017) Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies. Cancer 123(12):2283–2293. https://doi.org/10.1002/cncr.30616CrossRefPubMed

14.

Yang WC, Xiao F, Shih JY, Ho CC, Chen YF, Tseng HM, Chen KY, Liao WY, Yu CJ, Yang JC, Kuo SH, Cheng JC, Yang PC, Hsu FM (2018) Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery. Radiother Oncol 126(2):368–374. https://doi.org/10.1016/j.radonc.2017.10.010CrossRefPubMed

15.

Mazzola R, Fersino S, Ferrera G, Targher G, Figlia V, Triggiani L, Pasinetti N, Lo Casto A, Ruggieri R, Magrini SM, Alongi F (2018) Stereotactic body radiotherapy for lung oligometastases impacts on systemic treatment-free survival: a cohort study. Med Oncol 35(9):121. https://doi.org/10.1007/s12032-018-1190-8CrossRefPubMed

16.

Grimm J, LaCouture T, Croce R, Yeo I, Zhu Y, Xue J (2011) Dose tolerance limits and dose volume histogram evaluation for stereotactic body radiotherapy. J Appl Clin Med Phys 12(2):3368CrossRefPubMed

17.

Navarria P, Ascolese AM, Mancosu P, Alongi F, Clerici E, Tozzi A, Iftode C, Reggiori G, Tomatis S, Infante M, Alloisio M, Testori A, Fogliata A, Cozzi L, Morenghi E, Scorsetti M (2013) Volumetric modulated arc therapy with flattening filter free (FFF) beams for stereotactic body radiation therapy (SBRT) in patients with medically inoperable early stage non small cell lung cancer (NSCLC). Radiother Oncol 107(3):414–418. https://doi.org/10.1016/j.radonc.2013.04.016CrossRefPubMed

18.

Alongi F, Mazzola R, Figlia V, Guckenberger M (2018) Stereotactic body radiotherapy for lung oligometastases: literature review according to PICO criteria. Tumori 104(3):148–156. https://doi.org/10.1177/0300891618766820CrossRefPubMed

19.

Al-Shafa F, Arifin AJ, Rodrigues GB, Palma DA, Louie AV (2019) A review of ongoing trials of stereotactic ablative radiotherapy for oligometastatic cancers: where will the evidence lead? Front Oncol. https://doi.org/10.3389/fonc.2019.00543CrossRefPubMedPubMedCentral

20.

van Laarhoven HW, Kaanders JH, Lok J et al (2006) Hypoxia in relation to vasculature and proliferation in liver metastases in patients with colorectal cancer. Int J Radiat Oncol Biol Phys 64(2):473–482CrossRefPubMed

21.

Mazzola R, Tebano U, Aiello D, Di Paola G, Giaj-Levra N, Ricchetti F, Fersino S, Fiorentino A, Ruggieri R, Alongi F (2017) Increased efficacy of stereotactic ablative radiation therapy after bevacizumab in lung oligometastases from colon cancer. Tumori. https://doi.org/10.5301/tj.5000701CrossRefPubMed

22.

de Baere T, Auperin A, Deschamps F et al (2015) Radiofrequencyablation is a valid treatment option for lung metastases: experience in 566 patients with 1037 metastases. Ann Oncol 26:987–991CrossRefPubMedPubMedCentral

23.

Ahmed KA, Scott JG, Arrington JA, Naghavi AO, Grass GD, Perez BA, Caudell JJ, Berglund AE, Welsh EA, Eschrich SA, Dilling TJ, Torres-Roca JF (2018) Radiosensitivity of lung metastases by primary histology and implications for stereotactic body radiation therapy using the genomically adjusted radiation dose. J Thorac Oncol 13(8):1121–1127. https://doi.org/10.1016/j.jtho.2018.04.027CrossRefPubMedPubMedCentral

24.

Eschrich S, Zhang H, Zhao H et al (2009) Systems biology modeling of the radiation sensitivity network: a biomarker discovery platform. Int J Radiat Oncol Biol Phys 75:497–505CrossRefPubMedPubMedCentral

25.

Eschrich SA, Pramana J, Zhang H et al (2009) A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation. Int J Radiat Oncol Biol Phys 75:489–496CrossRefPubMedPubMedCentral

26.

Jingu K, Matsushita H, Yamamoto T, Umezawa R, Ishikawa Y, Takahashi N, Katagiri Y, Takeda K, Kadoya N (2018) Stereotactic radiotherapy for pulmonary oligometastases from colorectal cancer: a systematic review and meta-analysis. Technol Cancer Res Treat. https://doi.org/10.1177/1533033818794936CrossRefPubMedPubMedCentral

27.

Jung J, Song SY, Kim JH, Yu CS, Kim JC, Kim TW et al (2015) Clinical efficacy of stereotactic ablative radiotherapy for lung metastases arising from colorectal cancer. Radiat Oncol 10:238. https://doi.org/10.1186/s13014-015-0546-xCrossRefPubMedPubMedCentral

28.

Scorsetti M, Comito T, Tozzi A, Navarria P, Fogliata A, Clerici E et al (2015) Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer. J Cancer Res Clin Oncol 141:543–553. https://doi.org/10.1007/s00432-014-1833-xCrossRefPubMed

29.

Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, Lieu CH, Agarwal A, Maru DM, Sieber O, Desai J (2011) Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 117(20):4623–4632. https://doi.org/10.1002/cncr.26086CrossRefPubMed

30.

Gallaher IS, Watanabe Y, DeFor TE, Dusenbery KE, Lee CK, Hunt MA, Lin HY, Yuan J (2016) BRAF mutation is associated with improved local control of melanoma brain metastases treated with gamma knife radiosurgery. Front Oncol 6:107. https://doi.org/10.3389/fonc.2016.00107CrossRefPubMedPubMedCentral

31.

Robb R, Yang L, Shen C, Wolfe AR, Webb A, Zhang X, Vedaie M, Saji M, Jhiang S, Ringel MD, Williams TM (2019) Inhibiting BRAF oncogene-mediated radioresistance effectively radiosensitizes BRAF(V600E)-mutant thyroid cancer cells by constraining DNA double-strand break repair. Clin Cancer Res 25(15):4749–4760. https://doi.org/10.1158/1078-0432.CCR-18-3625CrossRefPubMedPubMedCentral

32.

Nicosia L, Gentile G, Reverberi C, Minniti G, Valeriani M, de Sanctis V, Marinelli L, Cipolla F, de Luca O, Simmaco M, Osti MF (2018) Single nucleotide polymorphism of GSTP1 and pathological complete response in locally advanced rectal cancer patients treated with neoadjuvant concomitant radiochemotherapy. Radiat Oncol J 36(3):218–226. https://doi.org/10.3857/roj.2018.00094CrossRefPubMedPubMedCentral

33.

Osti MF, Nicosia L, Agolli L, Gentile G, Falco T, Bracci S, Di Nardo F, Minniti G, De Sanctis V, Valeriani M, Maglio M, Borro M, Simmaco M, Enrici RM (2017) Potential role of single nucleotide polymorphisms of XRCC1, XRCC3, and RAD51 in predicting acute toxicity in rectal cancer patients treated with preoperative radiochemotherapy. Am J Clin Oncol 40(6):535–542. https://doi.org/10.1097/COC.0000000000000182CrossRefPubMed

34.

Lockney NA, Yang TJ, Barron D, Gelb E, Gelblum DY, Yorke E, Shi W, Zhang Z, Rimner A, Wu AJ (2017) PIK3CA mutation is associated with increased local failure in lung stereotactic body radiation therapy (SBRT). Clin Transl Radiat Oncol 7:91–93. https://doi.org/10.1016/j.ctro.2017.11.002CrossRefPubMedPubMedCentral

35.

Gomez DR, Tang C, Zhang J, Blumenschein GR Jr, Hernandez M, Lee JJ, Ye R, Palma DA, Louie AV, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Welsh JW, Gibbons DL, Karam JA, Kavanagh BD, Tsao AS, Sepesi B, Swisher SG, Heymach JV (2019) Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol 37(18):1558–1565. https://doi.org/10.1200/JCO.19.00201CrossRefPubMedPubMedCentral

36.

Valentí V, Ramos J, Pérez C, Capdevila L, Ruiz I, Tikhomirova L, Sánchez M, Juez I, Llobera M, Sopena E, Rubió J, Salazar R (2019) Increased survival time or better quality of life? Trade-off between benefits and adverse events in the systemic treatment of cancer. Clin Transl Oncol. https://doi.org/10.1007/s12094-019-02216-6CrossRefPubMed

37.

Mihai A, Mu Y, Armstrong J, Dunne M, Beriwal S, Rock L, Thirion P, Heron DE, Bird BH, Westrup J, Murphy CG, Huq MS, McDermott R (2017) Patients with colorectal lung oligometastases (L-OMD) treated by dose adapted SABR at diagnosis of oligometastatic disease have better outcomes than patients previously treated for their metastatic disease. J Radiosurg SBRT 5(1):43–53PubMedPubMedCentral

38.

Thibault I, Poon I, Yeung L, Erler D, Kim A, Keller B, Lochray F, Jain S, Soliman H, Cheung P (2014) Predictive factors for local control in primary and metastatic lung tumours after four to five fraction stereotactic ablative body radiotherapy: a single institution’s comprehensive experience. Clin Oncol (R Coll Radiol) 26(11):713–719. https://doi.org/10.1016/j.clon.2014.06.018CrossRef

39.

Jingu K, Matsuo Y, Onishi H, Yamamoto T, Aoki M, Murakami Y, Yamashita H, Kakuhara H, Nemoto K, Sakayauchi T, Okamoto M, Niibe Y, Nagata Y, Ogawa K (2017) Dose escalation improves outcome in stereotactic body radiotherapy for pulmonary oligometastases from colorectal cancer. Anticancer Res 37(5):2709–2713CrossRefPubMed

40.

Haderlein M, Lettmaier S, Langheinrich M, Schmid A, Semrau S, Hecht M, Beck M, Schmidt D, Grützmann R, Fietkau R, Denz A (2018) Repeating of local therapy of distant metastases increases overall survival in patients with synchronous metastasized rectal cancer—a monocentric analysis. Int J Colorectal Dis 33(11):1533–1541. https://doi.org/10.1007/s00384-018-3113-8CrossRefPubMed

41.

Greco C, Pares O, Pimentel N, Louro V, Morales J, Nunes B, Castanheira J, Oliveira C, Silva A, Vaz S, Costa D, Zelefsky M, Kolesnick R, Fuks Z (2019) Phenotype-oriented ablation of oligometastatic cancer with single dose radiation therapy. Int J Radiat Oncol Biol Phys 104(3):593–603. https://doi.org/10.1016/j.ijrobp.2019.02.033CrossRefPubMed

42.

Milano MT, Philip A, Okunieff P (2009) Analysis of patients with oligometastases undergoing two or more curative-intent stereotactic radiotherapy courses. Int J Radiat Oncol Biol Phys 73:832–837CrossRefPubMed

Titel: Disease course of lung oligometastatic colorectal cancer treated with stereotactic body radiotherapy
verfasst von: Luca Nicosia
Francesco Cuccia
Rosario Mazzola
Francesco Ricchetti
Vanessa Figlia
Niccolò Giaj-Levra
Michele Rigo
Davide Tomasini
Nadia Pasinetti
Stefanie Corradini
Ruggero Ruggieri
Filippo Alongi
Publikationsdatum: 12.05.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 9/2020
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-020-01627-7

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Disease course of lung oligometastatic colorectal cancer treated with stereotactic body radiotherapy

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2020

Modification of preoperative radiochemotherapy for esophageal cancer (CROSS protocol) is safe and efficient with no impact on surgical morbidity

Impact of 18F-FDG-PET/CT on the identification of regional lymph node metastases and delineation of the primary tumor in esophageal squamous cell carcinoma patients

Adjuvante Chemotherapie in der Behandlung der Urothelkarzinome des oberen Harntraktes

Assessment of DNA damage by 53PB1 and pKu70 detection in peripheral blood lymphocytes by immunofluorescence and high-resolution transmission electron microscopy

Stellenwert der Hippocampusschonung bei therapeutischer Ganzhirnbestrahlung

Effect of hypofractionation on the incidental axilla dose during tangential field radiotherapy in breast cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie